Treatment-resistant depression (TRD) is one of the most significant challenges in modern mental healthcare. Far from being an outlier, evidence suggests that failing to achieve remission after an initial antidepressant trial is the norm, not the exception. The landmark STAR*D trial revealed that only about one-third of patients achieve remission with their first medication. This reality requires clinicians to have a robust, evidence-based framework for navigating next steps when initial treatments fall short. This article distills key clinical pearls for managing TRD, from reassessing the diagnosis to implementing effective augmentation strategies.
Defining the Challenge and the Importance of Measurement
A common working definition for TRD, derived from clinical trials, is an inadequate response to at least two adequate medication trials. The key word here is “adequate.” An adequate trial is defined by three critical factors:
- Duration: Has the patient been on the medication for a sufficient period, typically at least six weeks?
- Dose: Has the medication been titrated to a therapeutic dose? This doesn’t always mean the maximum dose, but one that is typically effective.
- Adherence: Is the patient taking the medication consistently as prescribed?
Before identifying a person’s depression as treatment -resistant, it’s crucial to confirm that each of these conditions has been met.
Consistent, objective measurement is the cornerstone of effective depression treatment. Implementing measurement-based care, most commonly with the Patient Health Questionnaire-9 (PHQ-9), is essential. Administering the PHQ-9 at every medication management visit provides an objective benchmark for progress, helps identify treatment resistance early, improves patient outcomes, and increases remission rates. It transforms a subjective report into actionable data, guiding clinical decisions with greater precision.
Re-evaluating the Foundation: Diagnosis and Comorbidities
When a patient isn’t responding to treatment, the first step is to reconsider the fundamentals. Are you treating the right condition?
- Correct Diagnosis: Persistent depressive symptoms may point to an underlying condition that requires a different treatment approach. It’s vital to screen for bipolar disorder (assessing for any history of mania or hypomania), schizoaffective disorder, anxiety disorders, PTSD, and substance-induced disorders. Personality traits, such as those seen in borderline personality disorder, can also complicate treatment.
- Comorbid Medical Conditions: Unaddressed medical issues can mimic or exacerbate depression. Always consider screening for conditions like sleep apnea, thyroid dysfunction (both hypo- and hyperthyroidism), and chronic pain, as treating these can significantly improve mood symptoms.
- Substance Use: Ongoing use of substances—including alcohol, benzodiazepines, opioids, and cannabis—can significantly reduce the effectiveness of antidepressants and contribute to a depressive clinical picture.
The Central Role of Shared Decision-Making
Once you’ve confirmed the diagnosis and addressed comorbidities, the question becomes: what’s next? The evidence points to several viable options, including switching medications, augmenting with another medication, or adding psychotherapy. The most effective path forward is determined through shared decision-making.
Instead of searching for a single “best” option, the clinician’s role is to curate a few of the most reasonable, evidence-based choices and present them to the patient. Discuss the risks, benefits, and practicalities of each. When patients are actively involved in choosing their treatment path, we see improved satisfaction, engagement, and, most importantly, better adherence and clinical outcomes. This collaborative process honors patient autonomy and leverages the psychological benefit of being invested in one’s own care plan.
Augmentation: The Preferred Next Step
A significant shift in TRD management is the growing evidence supporting augmentation over switching antidepressants after a first failed trial. Augmenting—adding a second agent to the existing antidepressant—often leads to faster and higher rates of remission.
When pursuing augmentation, a key principle is to avoid polypharmacy. The goal should be a simple, two-medication regimen. If you find yourself prescribing three or more medications to treat a patient’s depression, it’s a critical moment to pause, re-evaluate the role of each agent, and seek consultation.
A Hierarchy of Augmentation Strategies
- Add Psychotherapy (when/if available): Consider adding therapy. Augmenting medication with an evidence-based psychotherapy like Cognitive Behavioral Therapy (CBT) is highly effective for TRD. A crucial long-term benefit is that skills learned in therapy lead to a lower risk of relapse after treatment discontinuation compared to medication alone. CBT via telehealth can be as effective as therapy delivered in-person. Telehealth may open up some options for patients.
- Augment with a Second-Generation Antipsychotic (SGA): There is robust and consistent evidence for the efficacy of SGAs as augmenting agents. Aripiprazole has the most extensive evidence base and often shows a greater effect than other options. However, this efficacy can come with a higher side effect burden, including akathisia. For patients who prioritize rapid symptom relief and are willing to tolerate potential side effects, this is a top-tier choice. If akathisia is a concern, brexpiprazole may be a better-tolerated alternative. Both medications have an FDA indication as adjunct treatment, but not monotherapy, for major depressive disorder.
- Augment with Another Antidepressant: Adding an antidepressant from a different class, such as bupropion or mirtazapine, is another effective strategy. Studies show this approach is nearly as effective as SGA augmentation but often with better tolerability and fewer side effects. This makes it an excellent option for patients who prioritize minimizing side effects.
- Consider Lithium: Lithium is a classic and effective augmentation agent, particularly valuable in patients with significant suicidal ideation due to its unique anti-suicide properties. However, the need for lab monitoring, as well as some specific risks (renal, thyroid, teratogen, etc.), place it further down the list for many clinicians, often considered after two different augmentation trials have failed.
Switching Antidepressants
Switching antidepressants typically involves trying a different antidepressant from a different class of antidepressants. Choosing from that new class of antidepressants is going to follow a similar strategy as outlined in last month’s newsletter on initial antidepressant selection and comes down to side effect profile, prior response, or comorbidities. Gene-drug interaction testing can provide additional insights into suggesting other options after two or more failed trials, but there is no guarantee for effectiveness. Switching from a low or moderate dose from a serotonergic medication to another serotonergic medication can be done rapidly by exchanging the old medication for an equivalent dose of the new antidepressant. Outside of that, a cross-taper method is preferred.
Advanced Treatments for Refractory Cases
When multiple medication and therapy trials have been unsuccessful, it’s time to consider neuromodulation.
- Transcranial Magnetic Stimulation (TMS): TMS is a non-invasive procedure with a solid evidence base for TRD. It is often covered by insurance after two or more failed medication trials and is a comfortable, well-tolerated procedure that can be highly effective.
- Electroconvulsive Therapy (ECT): For severe depression, particularly cases involving psychosis, catatonia, severe functional impairment, or acute suicidality, ECT remains the gold standard and should be strongly considered.
By adopting a systematic approach grounded in measurement, diagnostic diligence, and shared decision-making, clinicians can confidently and effectively guide patients through the complexities of treatment-resistant depression toward remission and recovery.
And remember, the UW Psychiatry Consultation Line (PCL) is always a resource to support you in the care of your adult patients with depression or any other mental health or substance use conditions. Prescribing providers can call any time, 24/7, and non-prescribing providers can call Mon-Fri, 8 AM – 5 PM (excluding holidays). 877-WA-PSYCH/877-927-7924 We are here to help!